Zydus Lifesciences Limited (NSE:ZYDUSLIFE)
India · Delayed Price · Currency is INR 996.10
+5.05 (0.51%)
Sep 2, 2025, 3:30 PM IST
Zydus Lifesciences Revenue
Zydus Lifesciences had revenue of 65.74B INR in the quarter ending June 30, 2025, with 5.90% growth. This brings the company's revenue in the last twelve months to 236.08B, up 14.52% year-over-year. In the fiscal year ending March 31, 2025, Zydus Lifesciences had annual revenue of 232.42B with 18.90% growth.
Revenue (ttm)
236.08B
Revenue Growth
+14.52%
P/S Ratio
4.25
Revenue / Employee
8.46M
Employees
27,917
Market Cap
1,002.31B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 232.42B | 36.94B | 18.90% |
| Mar 31, 2024 | 195.47B | 23.10B | 13.40% |
| Mar 31, 2023 | 172.37B | 21.28B | 14.08% |
| Mar 31, 2022 | 151.10B | 7.06B | 4.90% |
| Mar 31, 2021 | 144.04B | 1.50B | 1.06% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 537.77B |
| Divi's Laboratories | 96.52B |
| Cipla | 274.80B |
| Apollo Hospitals Enterprise | 225.51B |
| Mankind Pharma | 129.10B |
| Fortis Healthcare | 80.94B |
| Alkem Laboratories | 133.04B |
| Aurobindo Pharma | 320.25B |
Zydus Lifesciences News
- 4 days ago - Zydus Therapeutics Reports Positive Topline Results from EPICS-III Phase 2(b)/3 Trial of Saroglitazar Magnesium in Patients with Primary Biliary Cholangitis - Business Upturn
- 4 days ago - Zydus Therapeutics reports positive Phase 2b/3 trial results for Saroglitazar in Primary Biliary Cholangitis - Business Upturn
- 21 days ago - Stocks to watch on brokerages’ radar today, August 13: Minda Corp, Apollo Hospitals, Alkem Labs, Nykaa, Zydus Lifesciences, HAL, ONGC, NHPC, Honasa, Paytm - Business Upturn
- 21 days ago - Zydus Lifesciences Q1 net profit rises 3% to Rs 1,467 crore - The Times of India
- 21 days ago - Zydus Lifesciences Q1 Results: Revenue rises 5.9% YoY to Rs 6,573.7 crore, Net profit up 3.7% YoY - Business Upturn
- 22 days ago - Top Q1 results today, August 12: HAL, ONGC, Hindalco Industries, Zydus Lifesciences, Bharat Dynamics and more to announce earnings - Business Upturn
- 22 days ago - Zydus Lifesciences gets USFDA final approval for Diltiazem Hydrochloride tablets - Business Upturn
- 25 days ago - Zydus Lifesciences gets USFDA nod for Prucalopride tablets, 1 mg and 2 mg - Business Upturn